A new layer for Rosalind
OpenAI has acquired Orchestra Bio, a platform that helps drugmakers coordinate the complex process of drug development. Orchestra's team and technology will join Rosalind, OpenAI's initiative for life sciences research.
In the United States, bringing a medicine from target identification to regulatory approval typically takes 10 to 15 years. Scientific research is only part of that; even promising discoveries can slip when development teams struggle to keep complex projects on track.
What the agents do
Orchestra's AI agents can, for example after a failed manufacturing batch, gather relevant information, identify which milestones are affected and help teams weigh possible responses. OpenAI frames the tools as support for scientists and program managers rather than a replacement for scientific judgment.
OpenAI did not announce measurable targets for shortening development timelines through the acquisition. The company already runs AI partnerships with drugmakers including Novo Nordisk and Moderna.
